The impact of new epidemiological cutoff values on Candida glabrata resistance rates and concordance between testing methods

Diagnostic Microbiology and Infectious Disease

Volumn 79, Issue 2, 2014, Pages 209-213

  Ben Ami, Ronen ^a,b   Hilerowicz, Yuval ^b   Novikov, Anna ^a   Giladi, Michael ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antifungal drug resistance; Azoles; Candida glabrata; Echinocandins

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOOD; BROTH DILUTION; CANDIDA GLABRATA; CLINICAL LABORATORY; CLINICAL LABORATORY STANDARDS INSTITUTE; CONTROLLED STUDY; CORRELATION COEFFICIENT; EPIDEMIOLOGICAL CUTOFF VALUE; EPSILOMETER TEST; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REPRODUCIBILITY; RESPIRATORY SYSTEM; URINE; VAGINA; CANDIDIASIS; COMPARATIVE STUDY; DRUG EFFECTS; EVALUATION STUDY; FEMALE; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PREVALENCE; PROCEDURES; STANDARDS;

ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PREVALENCE; REPRODUCIBILITY OF RESULTS;

EID: 84900479812     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.02.008     Document Type: Article

References (29)

1. Alastruey-Izquierdo A., Gomez-Lopez A., Arendrup M.C., Lass-Florl C., Hope W.W., Perlin D.S., et al. Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology. J Clin Microbiol 2012, 50:2509-2512.
2. Alexander B.D., Johnson M.D., Pfeiffer C.D., Jimenez-Ortigosa C., Catania J., Booker R., et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013, 56:1724-1732.
3. Arendrup M.C., Garcia-Effron G., Lass-Florl C., Lopez A.G., Rodriguez-Tudela J.L., Cuenca-Estrella M., et al. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother 2010, 54:426-439.
4. Arthington-Skaggs B.A., Lee-Yang W., Ciblak M.A., Frade J.P., Brandt M.E., Hajjeh R.A., et al. Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother 2002, 46:2477-2481.
5. Bennett J.E., Izumikawa K., Marr K.A. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother 2004, 48:1773-1777.
6. bioMerieux. Etest antifungal susceptibility testing technical guide. AB Biodisk; 2007.
7. Clinical and Laboratory Standard Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard M27-A3. Wayne, Pa: National Committee for Clinical Laboratory Standards 2008.
8. Cornely O.A., Bassetti M., Calandra T., Garbino J., Kullberg B.J., Lortholary O., et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012, 18(Suppl 7):19-37.
9. Cuenca-Estrella M., Verweij P.E., Arendrup M.C., Arikan-Akdagli S., Bille J., Donnelly J.P., et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 2012, 18(Suppl 7):9-18.
10. Diekema D.J., Messer S.A., Hollis R.J., Boyken L.B., Tendolkar S., Kroeger J., et al. Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole. J Clin Microbiol 2007, 45:1974-1977.
11. EUCAST Definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008, 14:398-405.
12. Garcia-Effron G., Lee S., Park S., Cleary J.D., Perlin D.S. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother 2009, 53:3690-3699.
13. Garcia-Effron G., Park S., Perlin D.S. Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin. Antimicrob Agents Chemother 2011, 55:2245-2255.
14. Kartsonis N., Killar J., Mixson L., Hoe C.M., Sable C., Bartizal K., et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 2005, 49:3616-3623.
15. Lepak A., Castanheira M., Diekema D., Pfaller M., Andes D. Optimizing echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations. Antimicrob Agents Chemother 2012, 56:5875-5882.
16. Lockhart S.R., Iqbal N., Cleveland A.A., Farley M.M., Harrison L.H., Bolden C.B., et al. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol 2012, 50:3435-3442.
17. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., Hamill R.J., Larsen R.A., Horowitz H.W., et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003, 47:3149-3154.
18. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
19. Pfaller M., Neofytos D., Diekema D., Azie N., Meier-Kriesche H.U., Quan S.P., et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004-2008. Diagn Microbiol Infect Dis 2012, 74:323-331.
20. Pfaller M.A., Andes D., Arendrup M.C., Diekema D.J., Espinel-Ingroff A., Alexander B.D., et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011, 70:330-343.
21. Pfaller M.A., Andes D., Diekema D.J., Espinel-Ingroff A., Sheehan D. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010, 13:180-195.
22. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol 2010, 48:52-56.
23. Pfaller M.A., Castanheira M., Messer S.A., Moet G.J., Jones R.N. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis 2011, 69:45-50.
24. Pfaller M.A., Diekema D.J. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012, 50:2846-2856.
25. Pfaller M.A., Diekema D.J., Andes D., Arendrup M.C., Brown S.D., Lockhart S.R., et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011, 14:164-176.
26. Pfaller M.A., Diekema D.J., Boyken L., Messer S.A., Tendolkar S., Hollis R.J. Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole. J Clin Microbiol 2003, 41:1875-1880.
27. Sanglard D., Ischer F., Bille J. Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob Agents Chemother 2001, 45:1174-1183.
28. Shields R.K., Nguyen M.H., Press E.G., Kwa A.L., Cheng S., Du C., et al. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother 2012, 56:4862-4869.
29. Shields R.K., Nguyen M.H., Press E.G., Updike C.L., Clancy C.J. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother 2013, 57:3528-3535.